3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
2
Interventions
Oxaliplatin
56
Capecitabine
49
Fluorouracil
37
Cisplatin
37
S 1 (combination)
23
Paclitaxel
18
Docetaxel
18
Leucovorin
16
pembrolizumab
13
Irinotecan
12
apatinib
11
titanium silicide
9
XELOX
9
Trastuzumab
9
Nivolumab
9
Hyperthermic Intraperitoneal Chemotherapy
8
Epirubicin
8
Drug Therapy
8
Tegafur
7
Radiotherapy
6
Neoadjuvant Therapy
6
gimeracil
5
Surgical Procedures, Operative
5
Gastrectomy
5
Chemotherapy, Adjuvant
5
tislelizumab
4
S-1 plus cisplatin
4
Ramucirumab
4
zolbetuximab
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Stomach Neoplasms
×
rilotumumab
×
Clear all
NCT02137343
2016-04-04
RILOMET-2
Amgen
Phase 3
Terminated
34 enrolled
NCT01697072
2016-02-09
RILOMET-1
Amgen
Phase 3
Terminated
609 enrolled